Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Bayer to Initiate PIII Study of Xarelto for Prevention of MACE in Patients with CAD/PAD, Considers Study in Japan as Well
November 22, 2012
- Japanese Ethical Drug Market Shows Negative Growth in July-September for the First Time in 7 Quarters: IMS Japan
November 21, 2012
- Nexium Dominates HP and GP Markets from October: Rep Track Survey
November 21, 2012
- Sales Up 20% for 3 Major Generic-Only Companies in 1st Half of FY2012
November 21, 2012
- RaQualia to Obtain Substance Patent for APA in Japan
November 20, 2012
- Daiichi Sankyo Files Inavir for Prevention of Influenza Infection
November 20, 2012
- Kyowa Kirin President Hanai Indicates Certain Level of Understanding for “Health Economic Evaluation”
November 20, 2012
- Plan to Expand AZ-BMS Partnership in Diabetes “on Track”: AZ K.K. Pres. Hudson
November 19, 2012
- Toho HD Confident of Achieving 1% Full-Year Operating Profit Rate in Wholesale Business: Vice-President Kono
November 19, 2012
- Novartis to Revamp Marketing Structure in CNS Field, Shift from SOV
November 19, 2012
- Sawai Aims at Top Positions for New Products in Mediceo Utilizing Mediceo’s ARs: President Sawai
November 19, 2012
- E Keppra Grabs 20% Share of Domestic Anti-Epileptic Drug Market; Sales Growing Rapidly
November 19, 2012
- Medical System Network, Hanshin Dispensing Pharmacy to Set Up New Company for Drug Purchase Next April
November 16, 2012
- Nichi-Iko Aims to Initiate PI Study of Herceptin Biosimilar in FY2013: President Tamura
November 16, 2012
- 3 More Companies Temporarily Discontinue Marketing Generics Due to GMP Non-Compliance at South Korean Supplier
November 16, 2012
- Acquisitions Support Recovery in Leading Domestic Drug Makers’ Overseas Sales Ratio to 37%
November 15, 2012
- Shionogi, ViiV Obtain Favorable Results in 3rd PIII Clinical Trial for Dolutegravir
November 15, 2012
- Healthcare Sales Soar 4.4% with Expansion of Abilify in Japan: Otsuka HD
November 15, 2012
- OrphanPacific to Initiate New Business Model “Contract MAH for Overseas Pharma”
November 15, 2012
- Japan’s 25 Major Drug Makers Log Contrasting Domestic Biz Results on Varying New Product Performances
November 14, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…